Novartis phase II data for new inhaled combination treatment (QVM149) demonstrates significant improvements over current standard-of-care inhaled treatment

Brenda Snow
Authentic Patient Voice

David Linetsky
Point-of-Care Marketing

Joey Cohen
Medication Adherence

Daniel Sontupe
Market Access

Matt Turner
Patient Affordability

Matthew Durham
Omnidynamic Marketing

Pat Purcell
Meeting Engagement

Frank Burrell
Scientific Storytelling

Amy Giles
Increasing Engagement

Bud Bilanich
Success Coach

Liz Kane
Impactful Strategy

Paul Theisen
Patient Acquisition

Stacey Gandler
Brand Nourishment

Suma Ramadas, PhD
Medical Affairs